According to our new market research study titled “Late Stage Chronic Kidney Disease Drugs Market – Global Analysis and Forecast – by Product Type, Indication and Distribution Channel,” the market is expected to reach US$ 11,096.9 million by 2027 from US$ 4,680.0 million in 2019; it is estimated to grow at a CAGR of 11.6% during 2020–2027. The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth. The growth of the market is attributed to the key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00013768/
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. It affects more than 26 million Americans and millions more worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. 47% of new end-stage kidney disease (ESKD) patients had a primary diagnosis of diabetes, while 29% of new end-stage kidney disease patients had a primary diagnosis of hypertension. Moreover, according to Bayer’s press release, about 29 million people in the US have type 2 diabetes, and 40% will develop CKD in the coming year.
Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body’s needs. At this advanced stage of kidney disease, the kidneys have lost nearly all their ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live. The market is segmented by product type, indication, distribution channel, and geography.
The growth of the market is attributed to some key high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is likely to hamper the growth of the market during the forecast period.
Market Leaders:
Market leaders operating in the market have undertaken various organic growth strategies in the late stage chronic kidney disease drugs Market. The late stage chronic kidney disease drugs market majorly consists of the players such AbbVie Inc., Amgen, AstraZeneca, Sanofi, Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bayer AG, Vifor Pharma Management Ltd., and Akebia Drugs, Inc. among others. Several in organic approaches, such as mergers & acquisitions and collaboration in the late stage chronic kidney disease drugs market, have resulted in the positive growth of the market.
Have a Call with Analyst:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00013768/
Mergers & Acquisitions help the company to strengthen its revenue, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the late stage chronic kidney disease drugs market:
Jun-2020: Akebia Drugs announced the first regulatory approval of vadadustat in Japan, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
May-2020: Astellas Pharma Inc. announced the marketing authorization application (MAA) for roxadustat for the treatment of anemia in adult patients with chronic kidney disease (CKD) has been accepted by the European Medicines Agency (EMA) for regulatory review.
Jan-2020: AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in China for the treatment of adult patients with hyperkalemia (elevated levels of potassium in the blood).
Segments – By Product
Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Factors such as high prevalence of hyperparathyroidism, increased research studies on calcimimetics are some of the impacting factors which drive the segment growth. For instance, in February 2017, Amgen received the US Food and Drug Administration (FDA) approval for Parsabiv, an etelcalcetide, for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that is used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.
Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00013768/
About The Insight Partners:
The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.
Contact us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-987